HC Wainwright Weighs in on Kodiak Sciences FY2030 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Kodiak Sciences in a research note issued on Thursday, January 22nd. HC Wainwright analyst M. Caufield forecasts that the company will earn $1.12 per share for the year. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.09).

Several other research firms have also recently weighed in on KOD. Chardan Capital restated a “neutral” rating and set a $14.00 target price on shares of Kodiak Sciences in a research note on Monday, November 17th. Wall Street Zen cut Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Saturday, October 11th. UBS Group began coverage on Kodiak Sciences in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Finally, Lifesci Capital assumed coverage on shares of Kodiak Sciences in a report on Thursday, October 23rd. They issued an “outperform” rating and a $40.00 target price on the stock. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.29.

Kodiak Sciences Stock Performance

KOD stock opened at $25.86 on Friday. The company’s 50-day simple moving average is $25.40 and its 200 day simple moving average is $16.45. Kodiak Sciences has a 52 week low of $1.92 and a 52 week high of $31.18. The company has a market capitalization of $1.37 billion, a PE ratio of -6.28 and a beta of 2.67.

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC boosted its stake in shares of Kodiak Sciences by 1.2% during the second quarter. Acadian Asset Management LLC now owns 1,969,876 shares of the company’s stock valued at $7,343,000 after purchasing an additional 23,742 shares during the period. Vanguard Personalized Indexing Management LLC increased its stake in shares of Kodiak Sciences by 21.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock worth $56,000 after acquiring an additional 2,691 shares in the last quarter. Panagora Asset Management Inc. increased its position in Kodiak Sciences by 28.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock valued at $489,000 after buying an additional 29,113 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Kodiak Sciences in the 3rd quarter worth about $488,000. Finally, BNP Paribas Financial Markets raised its holdings in Kodiak Sciences by 89.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock worth $104,000 after acquiring an additional 3,009 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Insider Buying and Selling at Kodiak Sciences

In related news, Director Bros. Advisors Lp Baker acquired 2,608,696 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $23.00 per share, with a total value of $60,000,008.00. Following the acquisition, the director owned 18,358,772 shares of the company’s stock, valued at approximately $422,251,756. The trade was a 16.56% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 45.90% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.